Boundless and others head for phase 1
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.
Point’s big Splash falls short
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
Point looks to make a year-end Splash
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
